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Abstract
The discovery of genetic or genomic markers plays a central role in the development of personalized medicine. A notable
challenge exists when dealing with the high dimensionality of the data sets, as thousands of genes or millions of genetic
variants are collected on a relatively small number of subjects. Traditional gene-wise selection methods using univariate
analyses face difficulty to incorporate correlational, structural, or functional structures amongst the molecular measures. For
microarray gene expression data, we first summarize solutions in dealing with ‘large p, small n’ problems, and then propose
an integrative Bayesian variable selection (iBVS) framework for simultaneously identifying causal or marker genes and
regulatory pathways. A novel partial least squares (PLS) g-prior for iBVS is developed to allow the incorporation of prior
knowledge on gene-gene interactions or functional relationships. From the point view of systems biology, iBVS enables user
to directly target the joint effects of multiple genes and pathways in a hierarchical modeling diagram to predict disease
status or phenotype. The estimated posterior selection probabilities offer probabilitic and biological interpretations. Both
simulated data and a set of microarray data in predicting stroke status are used in validating the performance of iBVS in a
Probit model with binary outcomes. iBVS offers a general framework for effective discovery of various molecular biomarkers
by combining data-based statistics and knowledge-based priors. Guidelines on making posterior inferences, determining
Bayesian significance levels, and improving computational efficiencies are also discussed.
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Introduction
Biomarkers play a central role in the development and conduct
of translational and personalized medicine [1]. They are used in
predicting the progression of disease (prognosis markers), selecting
treatment regimes (predictive markers), screening diseases (diag-
nostic markers), and assisting with other forms of health related
tasks. Genomic biomarkers have already been applied for making
critical decisions, e.g., the Oncotype Dx test for quantifying risk of
disease recurrence in women with early-stage breast cancer and
for assessing the likely benefit from certain types of chemotherapy
[2]. The most notable challenge in molecular biomarker discovery
is caused by high-dimensionality of the data sets. There are
thousands of genes in microarray data analysis [3] and millions of
single nucleotide polymorphisms (SNPs) in genome-wide associa-
tion studies (GWAS) [4] from which biomarkers are identified.
Traditionally, discovery of differential genes was achieved by
univariate analyses where each gene is considered individually,
e.g., the weighted voting scheme of Golub et al. [5], the partial
least squares of Nguyen et al. [6], and the Wilcoxon test statistic of
Dettleing et al. [7]. Such gene-wise comparison methods have to
deal with the multiple comparison problem. Although schemes
have been proposed in adjusting the study-wise type-1 error or
restraining false positive rates, there lacks an effective way to
explicitly incorporate correlational or functional relationships
between the genes. Without studying the interactions of genes
and their joint impacts on phenotype, the traditional gene-wise
methods barely offer any biological interpretation. An earlier trial
to link gene-wise tests together was seen in LIMMA [8] using the
idea of empirical Bayes [9]. It makes the analysis stable by
borrowing information across genes via Bayesian hierarchical
modeling and shrinkage estimator [10]. Similar to gene-wise
analyses, LIMMA still treats gene expressions as outcome variables
and compares them across experimental conditions.
A more straightforward approach is to treat disease status or
phenotype as the outcome variable while setting genes as
predictors. This arrangement is not only meaningful, but allows
for studying multiple genes’ joint impact on the outcome variable.
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Thereby, the task of biomarker identification naturally becomes a
problem of variable selection in fitting regression models. Standard
frequentist or likelihood-based variable selection schemes via
criterion assessment such as BIC and AIC or stepwise subset
selection algorithms become infeasible when the number of
variables p becomes large; see an extensive discussion in Miller
[11]. As an alternative solution, Bayesian variable selection (BVS)
not only provides intuitive probabilistic interpretation, but also
explores the model space efficiently in a stochastic way to ensure
that the models with high probabilities would show up earlier and
more frequently during a simulation process. This is the reason
that the first satisfactory scheme of BVS was called ‘stochastic
search variable selection (SSVS)’ [12]. The theory of SSVS was
further developed [13] and many other stochastic searching
schemes have been proposed, e.g., the simplified method of Kuo
and Mallick [14], the Gibbs variable selection [15], Geweke’s BVS
with block-updates [16], and the reverse jump MCMC algorithm
[17]. BVS algorithms were also extended to much wider settings,
e.g., generalized linear models (GLMs) [18,19]; multivariate
regression models [20]; and even mixed-effects models [21,22];
see O’Hara and Sillanpa¨a¨ [23] for a detailed review.
The first applications of BVS in the setting of n%p arose from
analyzing genetic data in the early 2000s. Examples include
Bayesian model selection in gene mapping studies [24,25] and
SSVS for identifying multiple quantitative trait loci [26–28]. Most
of the methods use hierarchical Bayesian modeling to enable
borrowing information from neighbors [29]. It is especially
noteworthy that BVS has been successfully applied to GWAS
data that contains millions of genetic variants or SNPs [30,31]. As
stated by Guan and Stephens [4], ‘‘even using relatively simple
MCMC algorithms, BVS can indeed produce useful inferences in
problems of this size (with thousands of SNPs)." For genomic data,
including genome sequencing and gene expression microarray
data, biomarker identification with full BVS strategies is becoming
popular. BVS resorts to hierarchical modeling to control the
model size while as much as possible allowing data structures to be
complex [32,33]. A fair number of BVS applications have been
demonstrated in the previous decade [34–36].
A recent focus in BVS development is on how to model
biological processes that involve gene or protein groups function-
ing in concert. A comprehensive understanding of such processes
would help to unravel disease mechanisms and to design more
effective therapeutical products [37,38]. Recent studies demon-
strate that evaluating changes in expression across pre-defined
gene sets often increases statistical power and produces more
robust results [8,39–42]. Therefore, an appropriate approach
eliciting biologically meaningful and informative priors for BVS is
a worthy pursuit [38,43,44].
Following the above review of BVS development history, a
generalized strategy called integrative BVS (iBVS) for biomarker
discovery is presented in the Methods section. We propose an
iBVS strategy with a novel prior called PLS g-prior for handling
covariance matrices with n%p and incorporating gene pathways
into the selection procedure. In the Simulation section, the above
iBVS for gene expression data with binary disease status is
validated using simulated data and compared with other standard
BVS routine. In the Application section, the strategy of iBVS is
illustrated using a practical Affymetrix microarray data set for
patients with stroke. Remarks and discussions are given in the
Discussion section.
Methods
Notations
Suppose that y1,    ,yn are n independent observations of the
outcome variable Y , which could be binary, count or continuous.
Each outcome is associated with a set of predictor variables
x1,    ,xp whose values form the matrix X :
X~(x1,    ,xp)~
x11 x12    x1p
x21 x22    x2p
..
. ..
. P ...
xn1 xn2    xnp
0
BBBBBBB@
1
CCCCCCCA
:
In microarray data, xij denotes the normalized level of
expression for the jth gene on the ith subject. The outcome
variable Y is said to have a distribution in the exponential family if its
probability density function can be written in the general form,
f (y; j,w)~ expfyj{b(j)
a(w)
zc(y,w)g. Most of the distributions that
we know such as Gamma, Beta, Poisson, and Gaussian
distributions are all members of the exponential family. When Y
follows an exponential family distribution, the GLM [45] is
introduced in studying the relationship between Y and X via
g(m)~Xb, ð1Þ
where g() is a link function after which the expected value of Y ,
m~E(Y ), is predicted by the linear combination of X1,:::,Xp.
Bayesian Variable Selection in GLMs
A fundamental task of regression analysis is to select which
subset of the predictors are used to predict or explain the variance
Y . When other features of the GLMs such as the choice of link
function are determined, the problem of variable selection is
equivalent to the task of model selection. This paper focuses on the
explicit way of Bayesian variable/model selection in which an
indicator vector c~(c1,    ,cp)’ is introduced where
cj~
1, if Xi is selected;
0 otherwise:

Then the equation of GLM can be rewritten as
g(m)~
Xp
j~1
Xjbj(c): ð2Þ
By specifying prior distribution of c and b (and possibly other
parameters such as residual variance in a linear regression model),
one applies Bayes rule to derive the posterior distribution
P(c,bDX ,Y )!P(c,b)P(Y DX ,c,b) from which to obtain the poste-
rior probabilities P(cDX ,Y ) for model selection (c [ C). Within the
scope of this article, we define BVS as a procedure of variable
selection based on the posterior marginal selection probabilities,
Integrative BVS Framework with Informative Priors
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P(cj~1DX ,Y )~
X
c[C
I(cj~1)P(cDX ,Y ) ð3Þ
which has the form of Bayesian model averaging (BMA) [46]. This
BVS selection probability P(cj~1DX ,Y ) calibrates the overall
strength of Xj in predicting Y across various models.
Depending on the specification the prior distribution, P(c,b),
many schemes of BVS have been proposed, e.g., independent
prior distributions (i.e., P(cj ,bj)~P(cj)P(bj)) [14] and Gibbs
variable selection where P(bj Dcj~0) is set as a ‘pseudo-prior’ [15].
The most influential scheme is the SSVS [12], which assumes that
P(cj ,bj)~P(bj Dcj)P(cj) with
P(bj Dcj)~(1{cj)N(0,s
2)zcjN(0,c
2s2), ð4Þ
a mixture of a concentrated Gaussian distribution (when cj~0)
and a diffused one (when cj~1 and c
2w1). Alternatively one may
specify P(bj Dcj)~(1{cj)d0(bj)zcjN(0,s2), which has a natural
interpretation and can be further extended to the multivariate
setting, i.e., the g-prior [47],
P(bDc)*N(0,g(X
0
cXc)
{1), ð5Þ
where Xc is the sub-matrix of X consisting of columns with cj~1,
and constant g can be fixed at n or estimated via empirical Bayes.
The g-prior is a conjugate prior; one may analytically integrate out
b from P(c,bDX ,Y ) to obtain P(cDX ,Y ) or P(cj DX ,Y )’s, which are
of primary interest in BVS.
Nonetheless, g-prior has an undesirable feature: as b^??,
B01?(1zg)
(p{n)=2, where B01 is the Bayes factor in favor of the
null model (i.e., the one with b~0). It is because of this Bayes
factor paradox that Jeffreys [48] rejected normal priors, and later
Zellner and Siow (ZS) [49] proposed the Cauchy prior,
P(bDc)*Ca(0,g(X
0
cXc)
{1): ð6Þ
From the viewpoint of objective Bayes [50], ZS-prior satisfies six
of the seven desirable features (e.g., consistency, predictive
matching, and invariance) for the choice of model prior, but it
does not lead to closed-form answers. It was then further extended
to the so-called ‘robust prior,’ which is formulated as the scale
mixture of normal distributions [51]. Please see Bayarri et al. [52]
and the reference therein for recent development of objective BVS
priors, e.g., intrinsic priors [53–55], expected posterior priors [56],
and integral priors [57].
The prior P(c) can be naturally set as c*Ppj~1 Bern(pi). When
there is no preference, we can simply let pj~p, i.e.,
P(c)~Ppj~1 p
cj (1{p)(1{cj ). The value of p can be set to control
the number of selected variables a priori. For a data set with 100
variable, setting p~0:01 implies that only one variable be selected
before observing the data. We do not recommend using
P(cj)~0:5 because it indicate equal probabilities (2
{p) for all
models and does not induce any multiplicity adjustment [58].
Alternatively, one may introduce a hyper prior distribution for p,
P(p)~Beta(a,b), which could provide automatic multiplicity
adjustment [59–61].
BVS When n%p
Note that most of the above discussion assumes nwp. When
BVS is applied to biomarker identification for genomic data where
it is often seen that n%p, we face many challenges. First, since the
size of model space (2p) increases exponentially with p, it becomes
an intimidating task for a thorough search among all genes. Even
with stochastic searching strategy, the MCMC sampling algorithm
has a large computational burden at the level O(n2p2). Second,
among the p genes, many of them are ‘noisy’ variables in the sense
that they either have low quality such as missing or censored
values or do not participate the biological processes under study.
Blindly including them into the analysis would make the modeling
procedure time consuming or end up with invalid conclusions.
Third, the rank of matrix, X
0
cXc, would be much smaller than DcD,
the number of selected genes, making the matrix inversion
impossible. Fourth, there are many genes whose expressions are
highly correlated, easily leading to singularities in setting priors as
well as deriving the posterior distributions. These between-gene
correlation or causal structures, on the other hand, cannot be
simply ignored.
iBVS–A Generalized Framework of BVS. To solve the
above problems, we could have two options: (1) to restrain the size
of model space to a level that BVS can be accomplished within
acceptable amount of time; and (2) to apply the principle of
parsimony to reduce the number of model parameters via
regularization and shrinkage estimators. In this article, we provide
a generalized 2-step procedure called iBVS.
Step One is a ‘robust’ screening process aiming to directly
reduce the dimension p by removing genes with little useful signal
or those having no known biological relationship to the target
disease or phenotype. By ‘robust’ screening, we mean to use the
combination of various criteria jointly to ensure that enough genes
are included for Step Two. For example, we can first conduct
gene-wise t-tests to remove genes with p-values larger than a pre-
specified cut-off level (e.g., 0.01) that is much higher than the level
after a multiplicity adjustment. Among the excluded genes, we
may conduct gene-wise Wilcoxon test to further verify that no
gene has a p-value smaller than 0.05; otherwise the genes will be
moved back into the gene set. We may also move back those genes
that have been discovered to be functionally or structurally related
to the target disease or phenotype in the study. By curating public
data bases, we can generate a list of proteins that are functionally
related to the Y , and then find all the genes that code them. All
these genes would be moved back to the gene set for consideration.
We should also further move back additional genes that are
connected to any genes in the current set according to a specific
way of defining gene-gene networks, e.g., metabolic pathways [62]
and protein-protein interaction networks [63]. The final retained
set of genes is termed as the ‘signature set’ and used for Step Two.
The screening process may also allow investigators’ subjective
preferences and other methods such as the topological analysis of co-
expression network [64] and bagged gene shaving [65]. Here, we
emphasize that the screening is not purely just for dimension
reduction based on testing statistics. It is rather a key component of
iBVS for biomarker identification, which aims to create a broad
enough but biologically meaningful signature set for further
conducting BVS in the next step.
Step-Two of iBVS focuses on variable selection within the
framework of Bayesian hierarchical modeling (BHM) that aims to
investigate the joint distribution of genes in the signature set in
predicting phenotype or disease status. BHM offers a flexible way
in modeling complex structured data while restraining the number
of parameters. To reduce the computation burden of BVS for
Integrative BVS Framework with Informative Priors
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large p (number of signature genes), various strategies are
conceived. As seen in Godsill [66], and Yi [67], we can adopt
the ‘composite model selection’ principle and restrict that in each
MCMC iteration, only models with DcDvn are allowed to be
selected. This can be done by creating a special proposal
distribution in the Metropolis-Hastings (M-H) algorithm. Using
the idea of ‘Leaps and Bounds’ [68], Annest and Bumgarner et al.
[69] proposed the iterative model selection algorithm that first
orders all variables with a univariate selection method and then
moves a 30-variable window down the ordered variables. To
handle the problem of rank(X
0
cXc)vp, a direct solution is by Yang
and Song’s gsg-prior [70], which is the generalized inverse of X ’X
in Zellner’s g-prior. Ridge regression is also originated to handle
the problem of inverting a nearly singular matrix and Cholesky
decomposition is usually adopted to speed up the matrix inversion.
Some high-performance Gibbs samplers and M-H sampling
algorithms have been developed [71]. A straightforward solution
is to run multiple chains simultaneously (see Gelman and Rubin
[72]) on multiple virtual machines in computer clusters or using
Cloud Computing platforms. Some approximation methods are
also introduced trying to improve the computing speed, e.g., the
Matching Pursuit method [73,74].
In this paper, we proposed an iBVS with novel prior called PLS
g-prior in dealing with large p problems and with informative prior
on variable selection that reflect the gene-gene networks using
Markov random field (MRF).
Incorporate Informative Priors
Meaningful prior information may come from different sources,
including published literature, online knowledge bases, and
empirical experience of the investigators. However, it is still not
completely clear how to best use them or relate them effectively in
variable selection [75]. The most convenient way for informative
prior elicitation is to incorporate the relative frequencies of
identified biomarkers from published literature or from investiga-
tors’ subjective preference. For example, Kitchen et al. [76] used
results from the scientific literature when constructing several
informative exchangeable subset selection priors.
A more comprehensive approach is by adopting the view of
systems biology, which studies biological processes as whole
systems instead of isolate parts. For many diseases, expression-
based classification alone do not achieve high accuracy because
changes in expression of the few genes causing disease can be
subtle compared to those of the downstream effectors, which vary
considerably from patient to patient. A more effective means of
marker identification is to combine expression measurements over
pathways and identify which pathways act as markers in predicting
or explaining phenotypes. Here pathway refers to a group of
Figure 1. An Example of KEGG Pathway.
doi:10.1371/journal.pone.0067672.g001
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functionally or structurally related genes that jointly form a
network. Several pathway- or network-based marker identification
approaches have been proposed recently, e.g., Chuang et al. [77]
integrates expression profiles with pathways extracted from protein
interaction networks and Lee et al. [78] does so by adopting
pathways curated from literature. Large protein-protein interac-
tion networks have recently become available for human, enabling
new opportunities for elucidating pathways involved in major
diseases and pathologies. This network-based marker discovery
approach has shown success in diagnosis of metastatic breast
cancer [77] as well as classification of cell fate decisions during
development [79].
In this article, we combine the idea of gene- and network-based
marker discovery and provides an iBVS framework for identifying
contributive genes and important pathways. Informative priors on
pathway definition could come from publicly available literature
and databases: (1) DNA-sequence data (e.g., GeneBank and EBI);
(2) RNA sequence data (e.g., NCBI and Rfam); (3) GWAS data
(e.g., dbSNP and HapMap); (4) protein sequence data (e.g.,
UniProt, PIR and RefSeq); (5) protein class and classification (e.g.,
Pfam, IntDom, and GO); (6) gene structural (e.g., ChEBI, KEGG
ligand Database, and PDB); (7) genomics (e.g., Entrez Gene,
KEGG, and MetaCyc); (8) Signaling pathway (e.g., ChemProt and
Reactome); (9) metabolomics (e.g., BioCycy, HMDB, and
MMCD); (10) protein-protein interaction (e.g., IntAct, DIP,
MiMI). These databases could help us define pathways or
networks upon which to map our gene expression data under
analysis. Using the available biological information on inter-
connectivities and interactions between genes, we aim to discover
pathways that are associated with a specific biological process.
Srivastava et al. [80] have employed the GO information into
Figure 2. Gene and Pathway selection results in Scenario 1. The top figure corresponds to the posterior distribution of gene with effect size
b~(1:5,3:0,2:0,2:0), and second figure b~(0:375,0:75,0:5,0:5). The two smaller figures on the bottom demonstrate the posterior pathway selection
probabilities, with the left one corresponding to b~(1:5,3:0,2:0,2:0), and right one b~(0:375,0:75,0:5,0:5). The labeled red lines indicate causal
genes or causal pathways (those containing causal genes). These distributions were obtained by averaging over the 100 simulated sets of data.
doi:10.1371/journal.pone.0067672.g002
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their priors, and Stingo et al. [38] have used KEGG network
information.
There are also many other types of public data that may not be
used directly to construct pathways, but could be used directly for
deriving prior distributions for the current model. For example, by
searching literature (PubMed and Google Scholar) or reanalyzing
older gene expression data from GEO, ArrayExpresss, and
Oncomine, we could have some insights in determining the size
and form of the model before analyzing the data set at hand.
Many available clinical (e.g., OMIM, GeneCards, and Cancer-
Genes) or drug databases (e.g., DrugBank and SuperTarget) could
also provide structural or semi-structural information for us to
restrain model space and parameters.
Posterior Inference
As was mentioned in section 1, when the posterior space is huge,
we usually use the MCMC simulation to fit the posterior
distribution [81], instead of trying to obtain the exact values via
complicated calculations. The Gibbs sampler, and M-H sampler
are some of the well known Markov Chain Monte Carlo (MCMC)
algorithms. If possible, one should first analytically integrate out
the nuisance parameters (e.g., b, which is not of our main interest).
This can significantly speed up the MCMC simulation procedure.
As seen later, there are other ways to enhance the speed and
efficiency of MCMC, including various means to define the
proposal function in an M-H algorithm.
Once we obtain the samples from a MCMC procedure, we can
summarize them to estimate the posterior probabilities of selecting
genes and selecting pathways. In practice, certain guidelines
should be followed for making posterior inferences. The setting of
Figure 3. Gene and Pathway selection results in Scenario 2. The top figure corresponds to the posterior probabilities of gene selection with
effect size b~(3:0,2:0), and second figure b~(0:75,0:5). The two smaller figures on the bottom demonstrate the posterior probabilities of pathway
selection, with the left one corresponds to b~(3:0,2:0), and right one b~(0:75,0:5). The red lines indicate causal genes or causal pathways (those
containing causal genes). These distributions were obtained by averaging over the 100 simulated sets of data.
doi:10.1371/journal.pone.0067672.g003
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a cut-off for the important genes and pathways should adopt the
cross-validation strategy. As many research papers have shown, in
comparison to choosing one single best model, Bayesian model
averaging (BMA) would provide a better performance in
prediction problems [82]. It is also possible that different models
be used for variable selection and for making prediction or
classifying samples using the selected variables; model selecting
and making predictions are often viewed as two different goals.
iBVS for Biomarker Identification with Binary Outcome
In this section, we illustrate our iBVS method for biomarker
identification for gene expression data with binary outcomes. Here
we employ Bayesian hierarchical modeling approach to do gene
Figure 4. Posterior Gene Selection Probabilities when P=2000. The top figure shows the result for Scenario 3, and the bottom one Scenario
4.
doi:10.1371/journal.pone.0067672.g004
Figure 5. Mean Square Error for Gene Selections. Averaged over 100 simulated data in Scenario 1 for two set of gene effect sizes b. The top one
is for b~(1:5,3:0,2:0,2:0) and bottom one b~(0:375,0:75,0:5,0:5).
doi:10.1371/journal.pone.0067672.g005
Integrative BVS Framework with Informative Priors
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selection and pathway selection simultaneously and the PLS g-
prior is introduced.
Suppose our gene expression data have up to K pathways, we
denote the pathway membership by the matrix S (Sij~1 if the j
th
gene belongs to ith pathway; Sij~0 otherwise), and denote gene-
gene network by the matrix R (Rij~1 if there is a direct edge
between the ith and jth genes; Rij~0 otherwise). In addition to
using the indicator c~(c1,:::,cp)’ for gene selection, we introduce
another indicator j~(j1,    ,jK )’ for pathway selection, where
jk~1 (or 0) if the k
th pathway is selected (or excluded). When the
outcome variable Yi is binary, the Probit model of Albert and
Chib [83] is applied,
Yi~
0, if Ziƒ0,
1, if Ziw0:

where the latent variable Zi is assumed to have the standard
normal distribution, i.e.,
Zi~az(T(j,c)b(j,c))izEi,
Ei*N (0,1), i~1,    ,n,
ð7Þ
where b(j,c)~(b(k1,c),    b(kDjD,c)), T(j,c)~(T(k1,c),    ,T(kDjD,c)),
with DjD denotes the number of selected pathways in predicting
Zi, and T(kl ,c) denotes the vector of first PLS component of Xkl ,c.
Note that Xkl ,c is the sub-matrix of X , consisting of only the
columns that correspond to selected genes in the selected kthl
pathway. Here, we use kl (l~1,:::,DjD) to index the number of the
lth selected pathway (i.e., jkl~1); e.g., when K~5 and
j~(0,1,1,0,0) is the pathway selection result, we have DjD~2,
k1~2, and k2~3.
Prior specification for regression parameters. Note that
since observation data Y and expression data X are usually
standardized, we’ll assume a*N (0,h), where h is usually chosen
as a large number to indicate that we have little prior information
on the value of a. As for the prior on b, some commonly used
priors include a mixture distribution of a two normals, one normal
and one point mass, or one point mass and one uniform; Zellner’s
g{priors, Zellner-Siow’s Cauchy priors, or equivalently a mixture
of infinitely many normals. Yang and Song [70] generalized g-
prior to the so called gsg-prior.
For our hierarchical model, we propose a generalized g-prior
called PLS g-prior,
b(j,c)Dc*N (0,c(T ’(j,c)T(j,c))z), ð8Þ
where (T ’(j,c)T(j,c))
z represents the Moore-Penrose generalized
inverse of T ’(j,c)T(j,c), similar to Yang and Song [70]. The name
comes from the fact that T(j,c) is the first PLS component of Xkc.
Note that this generalized inverse is well-defined for any matrix.
Prior specification for variable selection
indicators. Following the principles in setting priors on variable
selection indicators, we assume that the pathway selection
indicators fjkgK1 are independently Bernoulli distributed,
Figure 6. ROC Curves for iBVS and YS-BVS (Yang & Song’s BVS).
doi:10.1371/journal.pone.0067672.g006
Figure 7. Gene and Pathway Selection Results for Stroke Data.
doi:10.1371/journal.pone.0067672.g007
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p(j)~ P
K
k~1
w
jk
k (1{wk)
(1{jk ), 0ƒwkƒ1: ð9Þ
where wk indicates the proportion of pathways expected a priori in
the model. One may assume that wk follows a mixture distribution
of a Dirac Delta distribution and a Beta distribution:
p(wk)~rd0(wk)z(1{r)B(wk Da0,b0). If we integrate out the
hyper-parameters, a0 and b0, to get the marginal distribution of
j, we will end up with a product of Bernoulli distributions with
parameter wnewk ~
a0(1{r)
a0zb0
. Later on, we will omit the ‘‘new’’ in
superscript and still denote it as wk.
To take into account the pathway membership information for
each gene as well as the biological relationships between genes
within pathways as indicated by the matrix R, we follow Li and
Zhang [43] and Stingo et al. [38] and use a MRF to describe the
prior on each component of the gene selection indicator c,
p(cj Dci,i[Nj)! exp (cj(mzg
X
i[Nj
ci)), ð10Þ
Table 1. Top 30 genes selected using BVS on Stroke Data.
No BVS.ID Post.Prob. Probe.Set.ID Gene.Symbol Gene.Title
1 196 0.951 206177_s_at ARG1 arginase, liver
2 61 0.26 202635_s_at POLR2K polymerase (RNA) II (DNA directed)
polypeptide K, 7.0kDa
3 356 0.184 205067_at IL1B interleukin 1, beta
4 486 0.15 1552912_a_at IL23R interleukin 23 receptor
5 634 0.126 235086_at THBS1 thrombospondin 1
6 514 0.125 207445_s_at CCR9 chemokine (C-C motif) receptor 9
7 576 0.114 207113_s_at TNF tumor necrosis factor
8 103 0.096 203939_at NT5E 5’-nucleotidase, ecto (CD73)
9 541 0.091 206126_at CXCR5 chemokine (C-X-C motif) receptor 5
10 95 0.087 219308_s_at AK5 adenylate kinase 5
11 559 0.085 214146_s_at PPBP pro-platelet basic protein (chemokine
(C-X-C motif) ligand 7)
12 524 0.082 210549_s_at CCL23 chemokine (C-C motif) ligand 23
13 339 0.076 205291_at IL2RB interleukin 2 receptor, beta
14 530 0.074 216598_s_at CCL2 chemokine (C-C motif) ligand 2
15 472 0.071 205445_at PRL prolactin
16 343 0.069 207072_at IL18RAP interleukin 18 receptor accessory
protein
17 26 0.067 223359_s_at PDE7A phosphodiesterase 7A
18 397 0.066 211333_s_at FASLG Fas ligand (TNF superfamily, member 6)
19 1098 0.059 52255_s_at COL5A3 collagen, type V, alpha 3
20 394 0.058 241819_at TNFSF8 tumor necrosis factor (ligand)
superfamily, member 8
21 89 0.056 212739_s_at NME4 non-metastatic cells 4, protein
expressed in
22 158 0.056 203302_at DCK deoxycytidine kinase
23 334 0.055 205327_s_at ACVR2A activin A receptor, type IIA
24 448 0.054 210755_at HGF hepatocyte growth factor (hepapoietin
A; scatter factor)
25 119 0.054 205757_at ENTPD5 ectonucleoside triphosphate
diphosphohydrolase 5
26 346 0.053 205403_at IL1R2 interleukin 1 receptor, type II
27 344 0.053 206618_at IL18R1 interleukin 18 receptor 1
28 1107 0.053 204614_at SERPINB2 serpin peptidase inhibitor, clade B
(ovalbumin), member 2
29 560 0.052 215101_s_at CXCL5 chemokine (C-X-C motif) ligand 5
30 80 0.051 1553587_a_at POLE4 polymerase (DNA-directed), epsilon 4
(p12 subunit)
We list the detailed information on the top 30 genes. BVS.ID refers to the variables in the model: e.g. 196 refers to x196 in our model. Post.Prob. is the posterior
probability of the particular variable.
doi:10.1371/journal.pone.0067672.t001
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where m and g are tuning parameters that will be specified later,
and Nj is the set of neighbors of gene j within the selected
pathway. This is equivalent to the multivariate form
p(cDj)! exp (m1
0
pczgc
0Rc); here the 1p is the vector consisting
of p 1’s. There are other ways to take advantage of the MRF
information too, e.g., Wei and Li [84] took a form similar to
exp (mzg
P
i[Nj
(2ci{1)) to take into account the possible down-
regulating effect from neighbors.
In the above hierarchical model, we also need to include
constraints on (j,c) so that (a) no empty pathways will be included;
(b) no gene will be selected unless the pathway containing it is
already selected; (c) adding or removing genes will not cause two
selected pathways having identical sets of selected genes. Any
violation to these three constraints will lead to an invalid
configuration. Thus, we end up with the joint distribution of
(j,c) in the following form, except for invalid configurations where
0 probability will be assigned:
p(j,c)! P
K
k~1
w
jk
k (1{wk)
(1{jk) exp (m1
0
pczgc
0Rc): ð11Þ
Derivation of posterior distributions. The joint posterior
distribution of (Z,a,b(j,c),j,c) given (Y ,X ) is.
p(Z,a,b(j,c),j,cDY ,X )
! P
n
i~1
p(Zi DY ,X ,a,b(j,c),j,c)p(a)p(b(j,c)DX ,j,c)p(j,c)
!½exp ({
Pn
i~1 (Zi{a{(T(j,c)b(j,c))i)
2
2
)
P
n
i~1
I(Ai) exp ({ a
2
2h
)
|½exp ({b
0
(j,c)T ’(j,c)T(j,c)b(j,c)
2c
)
P
mj
i~1
l
{1
2
i  P
K
k~1
p
jk
k (1{pk)
(1{jk ) exp (m1
0
pczgc
0Rc),
ð12Þ
where I(Ai) is the indicator function and Ai is either
fZi : Ziw0g or fZi : Ziƒ0g corresponding to Yi~1 or Yi~0,
and l1,    ,lmj (mjƒK) are the nonzero eigenvalues of
(T ’(j,c)T(j,c))
z.
We integrate out a and b to obtain the joint posterior
distribution of (Z,j,c) as follows (See Text S1 for detailed
derivation):
p(Z,j,cDY ,X )!
1
DS(j,c)D
1
2
exp ({
Z’S{1(j,c)Z
2
)
| P
n
i~1
I(Ai)| P
Kj
k~1
p
jk
k (1{pk)
1{jk exp (m1
0
pczgc
0Rc),
ð13Þ
where S(j,c)~Inzh11
’zcT(j,c)(T ’(j,c)T(j,c))
zT ’(j,c).
Computation with MCMC Algorithms
To sample the posterior distribution, we use a hybrid Gibbs and
Metropolis-Hastings MCMC sampling technique, which consists
of the following:
(a) Sampling Z given Y ,X ,j,c : We can see from (13) that
p(ZDY ,X ,j,c)!N (0,S(j,c))
Xn
i~1
I(Ai): ð14Þ
In this article, we follow the method given in Devroye (1986) to
sample each element Zi from its univariate truncated normal
distribution p(Zi DZ({i),Y ,X ,j,c), where Z({i) is the vector of Z
without the ith element.
(b) Sampling (j,c) from p(j,cDY ,X ,Z) :
p(j,cDY ,X ,Z)!
1
DS(j,c)D
1
2
exp ({
Z’S{1(j,c)Z
2
)
P
Kj
i~1
p
ji
i (1{pi)
1{ji| exp (m1
0
pczgc
0Rc):
ð15Þ
The parameters (j,c) are updated using a Metropolis-Hastings
algorithm in a two-stage sampling scheme. The pathway-gene
relationships are used to structure the moves and account for the
constraints specified earlier. Details of the MCMC moves to
update (b,c) are similar to that given in Stingo et al. [38] and
consist of randomly choosing one of the following random move
types that will not give rise to invalid configurations as seen earlier.
Table 2. Top Pathways Selected via BVS.
No KEGG.ID Name Top.genes.extracted Total # of genes
1 Hsa05214 Glioma - Homo sapiens (human) BVS.ID356 (IL1B), BVS.ID486 (IL23R) 253
2 Hsa04060 Cytokine-cytokine receptor interaction
- Homo sapiens (human)
BVS.ID61 (POLR2K) 160
3 Hsa05222 Small cell lung cancer - Homo sapiens (human) BVS.ID196 (ARG1) 106
4 Hsa04623 Cytosolic DNA-sensing pathway
- Homo sapiens (human)
BVS.ID196 (ARG1) 55
5 Hsa04640 Hematopoietic cell lineage - Homo sapiens (human) 107
We list the 5 pathways that have the highest posterior probabilities. Top.genes.extracts refers to the gene with highest posterior probability within a pathway. and Total
# of genes refers to the total number of genes within a pathway.
doi:10.1371/journal.pone.0067672.t002
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Simulation Studies
Study Design
To verify the performance of iBVS and compare it with other
methods, we mainly conducted simulation studies using KEGG
pathways. First, we simulated gene expression data for p~315
genes that involves in K~19 pathways as defined in the KEGG
database. From the pathway structures defined, we obtained the
pathway membership matrix S (i.e., a 315|19 matrix; Sij~1 if
the ith gene belongs to jth pathway, Sij~0 otherwise) and gene-
gene connection matrix R (i.e., a 315|315 matrix; Rij~1 if there
is a direct edge between the ith and jth genes, Rij~0 otherwise).
Then we simulated the binary outcome variable, Yi , which was
generated using the probit model with a latent variable Zi. By
applying iBVS algorithm with PLS g-prior to these synthesized
data with know causal genes, we aimed to assess its sensitivity and
specificity for gene selection. To further verify that iBVS could be
applied in a practical setting with large number of genes, we also
synthesized data with p~2000. Finally, we also compared iBVS to
a BVS strategy that does not employ informative priors.
Each KEGG pathway can be approximately viewed as a
Bayesian Network (BN), as illustrated in Figure 1. For the case of
p~315, we first merged all pathways into one large 315-gene BN
to take into account the genes on multiple pathways. Then we
simulated expression values for all the ‘root genes’ (those without
parental genes directing to them in the BN) using independent
standard normal distributions. Then, the expression values of their
child nodes were simulated using the idea of structural equation
modeling, i.e., Xi~
P
j[Pa(i) wijXjzei, where ei*N(0,0:5) and
wij ’s were random weights to ensure that
P
j[Pa(i) wij~1.
Repeating this procedure, we created 100 samples of expression
values for the 315 genes. Then we standardized all the genes’
expression values to ensure Xi*N(0,1) (i~1,    ,315).
To simulate binary outcomes, latent variables Zi’s were first
simulated according to the equation Zi~azXibizEi, where
a~{1:5 and Ei*N(0,1) (i~1,    ,100). Then, the binary
outcome Yi is set to be 1 if Ziw0, otherwise it is set to be 0.
Four scenarios of simulation are conducted based on the number
of causal genes and number of total genes.
Scenario 1
For p~315, we chose only 8 causal genes: ½X21,X25,X30 from
the 2nd pathway; ½X95,X102 from the 6th pathway; ½X290,X295
from the 18th pathway; and ½X234 is shared by the 13th and 14th
pathways. More specifically, we have.
E(Zi)~az(X21zX25zX30)b1z(X95zX102)b2
z(X234)b3z(X290zX295)b4
ð16Þ
where a~{1:5 was fixed, while two levels of gene effect size (i.e.,
b ) were considered: b~(1:5,3:0,2:0,2:0) vs.
b~(0:375,0:75,0:5,0:5). To evaluate the impact of correlation
structure on gene/pathway selection, the 2nd pathway was pre-
specified with highly correlated member genes (51% gene-gene
correlation coefficients were larger 0:6 or smaller than{0:6), the
6th pathway with lowly correlated members (96% gene-gene
correlation coefficients were between -0.20 and 0.20), and the 18th
pathway with mixed high and low correlations.
Scenario 2
Still for p~315, all 19 genes in the 6th pathway and all 9 genes
in the 15th pathway were set as causal genes, i.e.,
E(Zi)~az(X87z   zX105)b1z(X252z   zX260)b2 ð17Þ
where a~{1:5 was fixed and (b1,b

2) were set as (3:0,2:0) or
(0:75,0:5). As mentioned above, the 6th pathway mainly contains
genes that are weakly correlated. The 15th pathway has both
strong and weak correlations (28% gene-gene correlation coeffi-
cients with absolute value larger than 0:6; 67% smaller than 0:2).
Scenario 3
To consider the much higher dimensional situation, we
extended our simulation studies for Scenario 1. We kept the
original sample size of 100, number of causal genes at 8, effect size
b~(1:5,3:0,2:0,2:0), but this time added 1685 more randomly
generated non-causal genes, corresponding to 81 more artificial
pathways. Hence, the total number of genes in each data set is
2000, belonging to 90 pathways, and the R matrix (i.e., with
elements valued at 1 or 0 to indicate pairwise gene-gene
connectivity) is 2000|2000.
Scenario 4
To study the case of large grouped causal genes as seen in
Scenario 2, we artificially set 50 causal genes from 5 pathways (i.e.,
genes numbered 40–49, 305–314, 950–959, 1320–1329, 1710–
1719) with causal-effect set as 1.0 for the 1st 10 causal genes, 2.5
for the 2nd 10 causal genes, and similarly 1.5, 3.5, and 1.2 for
other three groups. For the 1st and 2nd gene sets, the pathways
they belong to were drawn from the KEGG database with many
gene-gene connections; but for the 3rd, 4th, and 5th sets of causal
genes, the pathways they belong to were purposedly constructed
with no gene connected to other genes.
Parameter specification and MCMC sampler. For each
scenario with each choice of effect size, we repeated the above
procedure to create 100 data sets, each consisting of 100 samples.
Each data set was fed to the iBVS algorithm for the selection of
important genes, where we set hyper parameters as
h~0:1, c~10000, wk~0:02, m~{3, g~0:08. Using Gelman
and Rubin diagnostics [72], the burn-in length was set at 10000
iterations after which 50000 additional iterations were run for
making posterior inference on each data set. The posterior gene/
pathway selection probabilities were then averaged across 100
data sets to assess the performance of BVS and the averaged
selection probabilities are depicted in Figures 2 and 3. For each
MCMC run on one set of data, it took about 10 minutes using a
fairly fast desktop computer (Windows 7, with 4 core 2.3 GHz
CPUs and 4 Gb memory). For the same task with p~2000, it took
54 minutes, which is still an acceptable speed.
Simulation Results
Posterior selection probabilities for p=315. In Scenario 1,
Figure 2 depicts the posterior gene/pathway selection probabil-
ities, averaged over the 100 simulated sets of data, for the two
levels of effect sizes. The labeled red lines indicate causal genes in
the left plots and the ‘causal pathways’ (those containing causal
genes) in the right plots. When the gene effect size was set as
b~(1:5,3:0,2:0,2:0), the ‘signal-to-noise ratio (SNR)’ is as high as
54.5 and it is a relatively easier task of gene selection. One
observes that our iBVS with PLS g-prior did a great job; all the
eight genes with the highest posterior probabilities are exactly the
same preset causal genes, and the five top pathways are exactly the
same causal pathways.
In comparison, when the effect size was set as
b~(0:375,0:75,0:5,0:5), the SNR becomes 3.4, which makes it
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a much harder job for gene selection. Even for this challenging
task, our iBVS works fairly well. Although some non-causal genes’
averaged selection probabilities stand out, even higher than those
of several causal genes, these non-causal genes are meaningful
markers in the sense that they belong to causal pathways and are
highly correlated with the causal genes. For example, X305 has a
higher selection probability than X290, but it belongs to a causal
pathway (the 18th pathway) and has a correlation coefficient of
0.86 with the causal gene X290. For two highly-correlated genes
within one pathway, it does not make much difference which one
is selected to act as the ‘marker’ in the conduct of personalized
medicine.
As for influence of correlation structures, first in the 6th
pathway, genes are weakly correlated, hence the causal genes are
clearly selected out. In the 2th pathway, genes are highly
correlated, we see that non-causal genes also have relatively high
posterior selection probabilities and the cut between causal and
non-causal is not that clear. This is especially seen in the case with
smaller effect size. As one expects, the contribution of a pathway in
predicting the outcome Y should be determined not only by the
effect sizes of causal genes in it, but also by the number of causal
genes in it. This is exactly the result observed from the iBVS
strategy. For example, gene X234 is a causal gene, belonging to
both the 13th and 14th pathways. Hence we see that both pathways
stand out from non-causal pathways, but at the same time their
averaged posterior selection probabilities are lower than that of the
18th pathway because the latter has two cause genes (X290 and
X295), each having equal effect size with X234.
In Scenario 2 all genes in pathways 6th and 15th are causal genes.
Plots in Figure 3 clearly show that the two groups of genes tend to
have higher posterior probabilities whether the effects of causal
genes are high or low. It is even clear that the top two causal
pathways stand much higher above the rest in terms of posterior
selection probabilities. Comparing the 6th and 15th pathways, it is
seen that the former has a relatively lower pathway selection
probability, although it has larger number of genes and each of the
gens has stronger caul effect (i.e., b1wb

2). An interpretation is that
the 6th pathway contains genes that are highly correlated; hence
the effective degrees of freedom is smaller than that of the 15th
pathway. Once again, this proves that not only the number of
causal genes, but the correlation structure between genes would
affect the selection of pathway in predicting disease or phenotype.
It is also noted that pathways 8 and 19 and their member genes
tend to have higher selection probabilities as seen from the plots.
This is because some of the genes in these two pathways are highly
correlated with some of the causal genes in the 6th and 15th genes.
The higher absolute level a non-causal gene is correlated with
some causal genes, the higher the posterior selection probability
would be observed for it. This is also the reason that in practical
settings, marker genes instead of causal genes are often identified.
We also found that the direction of the correlation coefficient
would not affect the selection probability of a marker gene; that is,
the correlation coefficient of 0:6 or{0:6 between non-causal gene
A and the causal gene B would lead to the same increase of A’s
selection probability.
Posterior selection results for P=2000. For Scenario 3, the
posterior gene selection probabilities, averaged over 100 sets of
simulated data are shown in the top part of Figure 4. All the casual
genes (marked by red color) still show significantly higher posterior
selection probabilities than other genes. This further verified that
our iBVS method works well for the case with p = 2000 genes, a
number that we believe is commonly encountered in practical
applications, as the majority of genes are unchanged between
conditions or expressed at baseline levels. Compared to the
simulation result with p = 315 genes, we found that the posterior
gene selection probabilities are much lower in the case of p = 2000.
For example, the selection probability for the causal gene 95,
reduced from 93.6% (when p = 315) to 72.4% (when p = 2000).
In Scenario 4, the bottom figure in Figure 4 shows that all the
casual genes (marked by red color) still show notably higher
posterior selection probabilities than other non-causal genes. But
this time, the cutoff between causal and non-causal gene selection
is not as clear as in Scenario 3. It is interesting to see that the
posterior selection probabilities are not that high for the 3rd, 4th,
and 5th causal gene groups. This is because the groups associate
with genes that are not connected to each other (in other words,
they independently influence the phenotype or disease status).
When groups of highly correlated causal genes are working in
concert, they jointly show higher impact to the phenotype or
disease status.
Determine significant causal or marker genes. When we
determine which or how many genes are significant causal or
marker genes based on the posterior probabilities distribution of all
genes, we use cross-validation methods. In this procedure, a
logistic regression model was used to examine the relationship
between genes and the binary outcome variable. We started from
simplest logistic regression model only including the gene with the
highest posterior probability. Then we add the gene with next
highest posterior probability to the model one at a time, until
reaching a total number of 30 genes included in model. Two
datasets were chosen randomly from 100 datasets, with one being
used for estimating the regression coefficients of the model, and
the other estimating the prediction error. We repeated this 200
times to find the average predicting error. The results of average
prediction error are shown in Figure 5 for b~(1:5,3:0,2:0,2:0)
and b~(0:375,0:75,0:5,0:5). It was clear in the first plot that the
model including the best eight genes had the lowest prediction
error, where the eight genes were exactly the same simulated
causal genes. In the second plot when b was smaller, we saw that
the model with 17 genes performed the best. Note that among the
17 genes 13 are causal genes and 4 are non-causal genes.
Compare iBVS with standard BVS. We further verified the
advantage of our iBVS method with informative priors construct-
ed from known gene-gene networks or pathways. To do this, we
compared our method with other standard BVS schemes without
informative priors. The method of Yang & Song [70] represents
such a standard BVS method, (will be referred as YS-BVS later
on), which is also the most comparable method to ours. In YS-
BVS procedure, pathway selection is not considered and the
existence of network relationships between the genes was
completely ignored.
We ran YS-BVS to the same sets of simulated data. The
following ROC curves for gene selection in two scenarios provide
a direct comparison of this method with ours on gene selection
accuracy in terms of sensitivity and specificity. From the plots in
Figure 6, it is obvious that both in the case of small number causal
genes (Scenario 1) and in the case of large number small-effect genes
(Scenario 2), our method has notably larger AUC (area under
curve). For example, the AUC is 0.992 for iBVS compared to
0.981 for YS-BVS in Scenario 1. This is especially true for Scenario
2 (AUC = 0.913 for iBVS and 0.750 for YS-BVS), which suggests
that in dealing with diseases of complete genomic mechanisms
involving many tiny-effect causal/marker genes, to consider gene
selection within the given network/pathway background would
definitely be a better approach for the task of biomarker
identification. And when applying both methods to simulated
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data with higher noise levels (see Figure 6), our iBVS has a greater
and significant advantage over YS-BVS.
Application
A blood-based biomarker of acute ischemic stroke is of
significant value in clinical practice. Deidentified data was used
from consented subjects recruited as part of the CLEAR Trial
from the University of Cincinnati (Pancioli et al. [85]). Ischemic
stroke was scored by clinical evaluation and evident by neuroim-
aging. Demographic information for stroke subjects and healthy
volunteers was recorded. Blood samples were drawn into
PAXgene tubes (PreAnalytiX, Hilden, Germany) within three
hours of stroke onset and prior to administration of any
medication. RNA was isolated, prepared and hybridized to
Affymetrix Human U133 Plus 2.0 microarrays as previously
described (Stamova et al. [86]) This study aimed to (1) identify
genes in differentiating stroke patients (v3-hr after stroke) from
healthy controls; and (2) identify pathways as groups of genes in
differentiating stroke patients from controls.
Analysis Procedure
A 2-step STS strategy for biomarker identification was adopted
in this application. Firstly, a robust gene screening and pathway
analysis was conducted; then followed by the conduct of
simultaneously selection of genes and pathways using the proposed
iBVS method.
We first selected 815 probe sets by using univariate t-test
(genefilter R package; rowttest) at significance level 10{9. These
probe sets correspond to 605 unique genes. By mapping these
genes to the KEGG database, we found 163 pathways, each
containing at least one of the 605 genes. These 163 pathways
contained 5467 genes in total. This group of genes was referred as
grand signature gene set and it contained too many candidate genes for
our iBVS discovery procedure.
To further reduce the number of candidate genes, we
considered two schemes. The first one was by conducting gene
set enrichment analysis (GSEA) based on the hypergeometric
distribution [40]. In this GSEA, each of the 163 pathways was
viewed as a gene set and the network topology was totally ignored.
By setting the p-value cut-off of 0:1, we kept 24 pathways for the
following iBVS analysis; all with pv0:1. These 24 pathways
contained a total of 1216 genes. For reference, these genes
together is termed Signature Gene Set. An alternative approach is to
subjectively select a small number of pathways according to their
known biological functions that are related to stroke or cardio-
vascular problems. This method was not applied because, unlike
protein-protein interaction networks, KEGG pathways offer less
clinical interpretation.
Since we only have microarray data defined on probe set level, a
procedure of mapping the probe sets to genes was also needed. We
followed the lead of Li et al. [87] to choose only one probe set to
represent the expression level of a gene. If multiple probe sets were
mapped to one gene, we kept the one with smallest p value in the
above multiple t-test procedure.
Finally we conducted the iBVS analysis with PLS g-prior by
considering only the Signature Gene Set and the associated 24
KEGG pathways. Then we followed the iBVS method for
binomial regression with Probit distribution to carry out the
variable selection. Similar hyper-parameters were set as in the
simulation studies and we used Gelman and Rubin diagnostics
[72] to determine the burn-in length as 10000 iterations and
50000 additional iterations were run to make posterior inferences.
It took 5 hours and 40 minutes using a desktop computer with
single core 4.5GHz CPU and 4GB memory.
Application Results
Figure 7 shows the posterior probabilities of genes selected via
our iBVS strategy with integrated biological priors. The top 30
genes (probe sets) are listed in Table 1. In order to select only the
most efficient predictive genes, cross-validation for our iBVS
model was used. The top genes were added into the logistic model,
one by one, to estimate the prediction error. The error analysis of
the model with inclusion of different numbers of predictive genes
shows that the smallest classification error appears when only the
top 3 or 4 genes are selected as predictors. The error increases
with the number of predictors of more than 4, but the errors
greatly decrease again when the 13th or 16th genes are included in
the model. The top 5 pathways are listed in Table 2.
From a biological standpoint, the genes and pathways that
represent the best gene predictors and key pathways are directly
relevant. ARG1, the gene with the greatest predictive value, is a
marker of M2 macrophage activation (Morris et al. [88]), which is
associated with the inflammatory and immune response to stoke.
Abrupt changes in gene transcription triggered as a response to
stroke for initiation of cellular survival mechanisms would be
mediated through POLR2K as a pivotal player in RNA
transcription. IL1B and IL23R are also amongst the other top
genes with the greatest predictive value. These and many others
identified in Table 1 are key modulators in effecting the
inflammatory response of cells responding to the injury of stroke
(Wong et al. [89]).
Given the abundance of chemokine and immune modulating
genes in our list, it was not surprising to see that the KEGG
pathway for cytokine-cytokine interaction is represented, as is the
highly immune pathway for cytosolic DNA-sensing. While gliomas
are brain-related like stroke, the presence of this pathway may
represent its more general cytokine or calcium-related signaling
features. Smaller overlapping sub-networks of characterized
pathways may account for the presence of seemingly unrelated,
yet identified pathways such as that for small cell lung cancer, as it
contains key components of cell proliferation and cell death, which
are also prominent in brain injury.
Discussion
In this paper, we used a generalized Bayesian framework for
biomarker identification. For problems with n%p, it would be
appealing to remove noisy measures or those with lower quality
beforehand and defining the proper level of model space to be
further explored using stochastic search. We then followed the
integrative biomarker discovery scheme to incorporate the gene
network, i.e. pathway information, and adopted a novel PLS g-
prior for the purpose of variable selection. Cross-validation
methods were conceived for determining the Bayesian significance
level in cutting off the posterior probabilities for selecting causal/
marker genes in classifying patients or predicting risk of diseases.
Subjective versus Objective Priors
In this paper, we mainly adopt the perspective of subjective
Bayesian due to the fact that we want to incorporate informative
priors from available scientific sources. Although we used MRF in
this article to illustrate how gene-gene networking structure would
cast upon gene selection, there are many different ways to use the
abundant informative priors (Hill et al. [75]). As seen in the
Method section, even for MRF, we have different ways to
incorporate this information. Choosing an objective prior that
satisfies some fundamental principles as summarized in Bayarri
et al. [52] would be theoretically appealing. For example, when
specifying the prior distribution of the gene/pathway selection
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probability, we may choose a Bernoulli distribution with unknown
hyper-parameter p with Beta prior distribution, instead of setting it
at a fixed level. This would lead to the posterior selection of models
that are not biased toward a mode dimension of p=2.
Comparison to Other Marker Discovery Methods
As mentioned above briefly, regularization methods provide an
alternative solution for feature selection and classification prob-
lems. For GWAS data, Guan and Stephens [4] have indicated that
BVS provides better power and predictive performance than
standard lasso techniques. Our experience with standard BVS for
simulated microarray data with continuous outcomes also suggest
that it outperforms lasso, elastic net [90], and stepwise variable
selection with higher sensitivity and specificity. Nonetheless, there
lacks of evidence in comparing BVS with grouped lasso [91],
which considers the grouping of genes into gene sets. As proved in
the simulation studies, our iBVS performs better than, or at least
equally as well as standard BVS for gene selection. It also has the
advantage to tell you which networks, in addition to which genes,
could predict disease and pathology. Compared to network-based
marker discovery, our iBVS not only suggests which genes are
important, but also could handle those ‘orphan’ genes that have
not been classified into any pathway at the time of study.
In the conduct of standard GSEA or network marker discovery,
one may calibrate the significance of a pathway in predicting
disease or treatment effectiveness by using all its predefined
member genes, but these include a large number of noisy genes
(i.e., those non-contributive and non-causal genes). Alternatively,
one may choose to use only a subset of contributing genes, but
which subset to use is a big challenge. In our iBVS, the two
components are merged together into one procedure, which allows
the two parts learn from each other and reflects the uncertainty of
gene/pathway selection using stochastic simulation.
Future Directions
Although iBVS has been proven as an appealing alternative
solution to traditional gene-wise biomarker identification, its
computational challenges hinder its widespread adoption. With a
large number of parameters in the model, the inference is mainly
based on Monte Carlo simulation, which is time-consuming.
Running over single computers, it would take hours even days to
complete a round of simulation procedure. Nowadays, with the
advent of high-speed cluster computers and the existence of cloud
computing technologies, it is becoming very feasible to apply full
iBVS methods for biomarker identification. Our research team is
developing parallel MCMC algorithm over the Amazon Cloud
platform using the idea of MapReduce.
Currently, the pathway information we have is limited to a
small portion of genes that have been well-characterized. A
relatively large amount of genes are not well-studied, nor their
functions have been identified. In our application, we found that
some genes had not been mapped to any KEGG pathways yet.
Two potential solutions are conceived: (1) develop a stochastic
inference of the gene-gene networks from the data and merge it
into the current BVS MCMC algorithm; (2) query the Internet to
find as more information, literature, and databases to help elicit
richer priors. This topic is part of our ongoing research.
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